{"protocolSection":{"identificationModule":{"nctId":"NCT01202227","orgStudyIdInfo":{"id":"A0081252"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain","officialTitle":"An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)"},"statusModule":{"statusVerifiedDate":"2013-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-09"},"primaryCompletionDateStruct":{"date":"2012-03","type":"ACTUAL"},"completionDateStruct":{"date":"2012-03","type":"ACTUAL"},"studyFirstSubmitDate":"2010-08-31","studyFirstSubmitQcDate":"2010-09-13","studyFirstPostDateStruct":{"date":"2010-09-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-01-10","resultsFirstSubmitQcDate":"2013-04-05","resultsFirstPostDateStruct":{"date":"2013-05-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-01-26","lastUpdatePostDateStruct":{"date":"2021-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain)."},"conditionsModule":{"conditions":["Spinal Cord Diseases","Spinal Cord Injuries","Neuralgia","Pain"],"keywords":["Central Nervous System Diseases","Therapeutic Uses","Wounds and Injuries","Trauma","Nervous System","pregabalin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":104,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pregabalin","type":"EXPERIMENTAL","description":"Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period","interventionNames":["Drug: pregabalin"]}],"interventions":[{"type":"DRUG","name":"pregabalin","description":"Pregabalin capsules taken twice a daily (150-600mg/day)","armGroupLabels":["Pregabalin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Peripheral Edema","description":"Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Facial/Periorbital Edema","description":"Number of participants who had facial or periorbital edema.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Generalized or Abdominal Edema","description":"Number of participants who had generalized or abdominal edema.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53"},{"measure":"Number of Participants With Visual Field Deteriorated","description":"Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).","timeFrame":"53 weeks"},{"measure":"Number of Participants With Deterioration in Neurological Examination Findings","description":"Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.","timeFrame":"53 weeks"},{"measure":"Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)","description":"The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores","description":"The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.\n\nRange: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52"},{"measure":"Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores","description":"The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.\n\nRange: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52"},{"measure":"Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores","description":"The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.\n\nRange: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52"},{"measure":"Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score","description":"The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from \"does not interfere\" (0) to \"completely interferes\" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale.\n\nChange = observation mean at Week 52 minus baseline mean.","timeFrame":"Baseline, Week 52"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion criteria for subjects to be shifted from Study A0081107\n\n* Subjects who completed the 18-week study period in Study A0081107 conducted for chronic neuropathic pain after spinal cord injury;\n* Subjects who completed assessments of all efficacy endpoints until the end of the treatment phase of the preceding Study A0081107 (V7);\n\nInclusion criteria for subjects to be new participants in this study\n\n* Subjects with central neuropathic pain after stroke or multiple sclerosis;\n* At least 6 months have passed after the onset of central neuropathic pain;\n* Pain VAS at least 40mm in Visit 1 and Visit 2;\n\nExclusion Criteria:\n\n* Creatinine clearance \\< 60 mL/min;\n* Platelet count \\< 100 × 103/mm3 ; White blood cell (WBC) count \\< 2500 / mm3; Neutrophil count \\< 1500/ mm3;\n* Subjects who are expected to require surgery during the trial;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Chubu Rosai Hospital","city":"Nagoya","state":"Aichi","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Kimura Clinic","city":"Nagoya","state":"Aichi","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Nagoya Kyoritsu Clinic","city":"Nagoya","state":"Aichi","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Senboku Kumiai General Hospital","city":"Daisen","state":"Akita","country":"Japan"},{"facility":"Go neurosurgical clinic","city":"Chikushi-gun","state":"Fukuoka","country":"Japan","geoPoint":{"lat":33.56055,"lon":130.78718}},{"facility":"Spinal Injuries Center","city":"Iizuka","state":"Fukuoka","country":"Japan","geoPoint":{"lat":33.63654,"lon":130.68678}},{"facility":"Brain Attack Center Ota Memorial Hospital","city":"Fukuyama","state":"Hiroshima","country":"Japan","geoPoint":{"lat":34.48333,"lon":133.36667}},{"facility":"Hokkaido Chuo Rosai Hospital Sekison Center","city":"Bibai","state":"Hokkaido","country":"Japan","geoPoint":{"lat":43.32472,"lon":141.85861}},{"facility":"Hakodate Central General Hospital","city":"Hakodate","state":"Hokkaido","country":"Japan","geoPoint":{"lat":41.77583,"lon":140.73667}},{"facility":"Kobe Tokushukai Hospital","city":"Kobe","state":"Hyogo","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Aida Kinen Rehabilitation Hospital","city":"Moriya","state":"Ibaraki","country":"Japan","geoPoint":{"lat":35.93333,"lon":140.0}},{"facility":"General Hanamaki Hospital","city":"Hanamaki","state":"Iwate","country":"Japan","geoPoint":{"lat":39.38333,"lon":141.11667}},{"facility":"Uchida Rehabilitation Orthopedic Clinic","city":"Kawasaki","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"Kumamoto Rehabilitation Hospital","city":"Kikuchi-gun","state":"Kumamoto","country":"Japan","geoPoint":{"lat":32.98333,"lon":130.81667}},{"facility":"Sendai Pain Clinic","city":"Sendai-city","state":"Miyagi","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Kohnan Hospital","city":"Sendai","state":"Miyagi","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"National Hospital Organization Niigata National Hospital","city":"Kashiwazaki","state":"Niigata","country":"Japan","geoPoint":{"lat":37.36667,"lon":138.55}},{"facility":"Nakamura Hospital","city":"Beppu","state":"Oita","country":"Japan","geoPoint":{"lat":33.27945,"lon":131.49751}},{"facility":"Kitasato University Kitasato Institute Medical Center Hospital","city":"Kitamoto","state":"Saitama","country":"Japan","geoPoint":{"lat":36.03322,"lon":139.53775}},{"facility":"Kamitsuga General Hospital","city":"Kanuma","state":"Tochigi","country":"Japan","geoPoint":{"lat":36.55,"lon":139.73333}},{"facility":"Juntendo University Hospital","city":"Bunkyo-ku","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.37517,"lon":139.92991}},{"facility":"Jukoukai hospital","city":"Koto-ku","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.66667,"lon":139.81718}},{"facility":"National Hospital Organization, Murayama Medical Center","city":"Musashimurayama-shi","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.74242,"lon":139.42635}},{"facility":"Okitama Public General Hospital","city":"Higashiokitama-gun","state":"Yamagata","country":"Japan"},{"facility":"Tokushima University Hospital","city":"Tokushima","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}},{"facility":"National Hospital Organization Yamagata Hospital","city":"Yamagata","country":"Japan","geoPoint":{"lat":38.23333,"lon":140.36667}}]},"referencesModule":{"references":[{"pmid":"25114584","type":"DERIVED","citation":"Onouchi K, Koga H, Yokoyama K, Yoshiyama T. An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. J Pain Res. 2014 Jul 28;7:439-47. doi: 10.2147/JPR.S63028. eCollection 2014."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081252&StudyName=An%20Open-Label%20Long-Term%20Study%20Of%20Pregabalin%20For%20The%20Treatment%20Of%20Central%20Neuropathic%20Pain"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants who had joined A0081107 study (NCT00407745) were treated with pregabalin or placebo for 16 weeks and underwent tapering phase prior to this study.","recruitmentDetails":"Japanese patients with central neuropathic pain after spinal cord injury who had completed the preceding A0081107 study (NCT00407745) were eligible for this study, and Japanese patients with pain after cerebral stroke or with multiple sclerosis pain were newly recruited.","groups":[{"id":"FG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Treated","numSubjects":"103"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"84"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"16"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"103"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":">=18 and <45 years","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]},{"title":">= 45 and <65 years","categories":[{"measurements":[{"groupId":"BG000","value":"60"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"81"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Peripheral Edema","description":"Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Trace at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Pitting +1 at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Pitting +2 at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Pitting +3 at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Trace at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Pitting +1 at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Pitting +2 at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Pitting +3 at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Trace at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Pitting +1 at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Pitting +2 at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Pitting +3 at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Trace at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Pitting +1 at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Pitting +2 at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Pitting +3 at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Trace at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Pitting +1 at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Pitting +2 at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Pitting +3 at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Trace at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Pitting +1 at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Pitting +2 at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Pitting +3 at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Facial/Periorbital Edema","description":"Number of participants who had facial or periorbital edema.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Generalized or Abdominal Edema","description":"Number of participants who had generalized or abdominal edema.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Mild at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Moderate at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Severe at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Mild at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Moderate at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Severe at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Moderate at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Moderate at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Moderate at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Mild at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Moderate at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Severe at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Mild at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Mild at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Moderate at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Severe at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Moderate at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Severe at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Moderate at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Severe at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Moderate at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Severe at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Moderate at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Moderate at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Mild at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Moderate at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Severe at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Moderate at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Severe at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Moderate at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Severe at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Moderate at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Moderate at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Moderate at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Mild at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)","description":"DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Mild at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Moderate at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 52/early termination (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mild at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Moderate at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Severe at Week 53/early termination (n=78)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Visual Field Deteriorated","description":"Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"53 weeks","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Right eye","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Left eye","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Deterioration in Neurological Examination Findings","description":"Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"53 weeks","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Cranial Nerve Function","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Mental State","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Coordination: Right (R)- Finger to Nose","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Coordination: Left (L)- Finger to Nose","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Coordination: R- Finger Tapping","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Coordination: L- Finger Tapping","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Coordination: R- Rapid Alternating Hand Movement","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Coordination: L- Rapid Alternating Hand Movement","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Coordination: Romberg Test","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Gait","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Deep Tendon Reflexes: R- Brachioradialis","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Deep Tendon Reflexes: L- Brachioradialis","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Deep Tendon Reflexes: R-Patellar","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Deep Tendon Reflexes: L-Patellar","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Deep Tendon Reflexes: R- Achilles","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Deep Tendon Reflexes: L- Achilles","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Abnormal Reflexes","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Muscle Strength: R- Upper Limb","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Muscle Strength: L- Upper Limb","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Muscle Strength: R- Lower Limb","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Muscle Strength: L- Lower Limb","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Muscle Tone: R- Upper Limb","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Muscle Tone: L- Upper Limb","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Muscle Tone: R- Lower Limb","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Muscle Tone: L- Lower Limb","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Sensory Function: Anesthesia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Sensory Function: Hypesthesia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Sensory Function: Allodynia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Sensory Function: Hyperalgesia","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)","description":"The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.","populationDescription":"The safety analysis set consists of all participants who received at least one dose of study medication in this long-term study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Baseline (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Week 2 (n=102)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Week 4 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Week 8 (n=99)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 12 (n=96)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 20 (n=93)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Week 28 (n=91)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Week 36 (n=90)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Week 44 (n=85)","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Week 52 (n=101)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores","description":"The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.\n\nRange: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.","populationDescription":"The full analysis set consists of all participants who received at least one dose of study medication in this long-term study and for whom post-treatment data were available. For study endpoint of efficacy (Week 52), missing values was imputed with the last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Week 2 (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","lowerLimit":"-5.4","upperLimit":"-3.0"}]}]},{"title":"Week 4 (n=102)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","lowerLimit":"-6.4","upperLimit":"-4.0"}]}]},{"title":"Week 8 (n=99)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","lowerLimit":"-6.6","upperLimit":"-4.0"}]}]},{"title":"Week 12 (n=98)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","lowerLimit":"-7.3","upperLimit":"-4.2"}]}]},{"title":"Week 20 (n=95)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","lowerLimit":"-7.6","upperLimit":"-4.7"}]}]},{"title":"Week 28 (n=92)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","lowerLimit":"-6.6","upperLimit":"-3.6"}]}]},{"title":"Week 36 (n=91)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","lowerLimit":"-6.5","upperLimit":"-3.5"}]}]},{"title":"Week 44 (n=87)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","lowerLimit":"-6.1","upperLimit":"-2.8"}]}]},{"title":"Week 52 (n=85)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","lowerLimit":"-6.6","upperLimit":"-3.4"}]}]},{"title":"Week 52 (LOCF, n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","lowerLimit":"-6.2","upperLimit":"-3.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores","description":"The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.\n\nRange: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.","populationDescription":"The full analysis set consists of all participants who received at least one dose of study medication in this long-term study and for whom post-treatment data were available. For study endpoint of efficacy (Week 52), missing values was imputed with the last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Week 2 (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","lowerLimit":"-4.1","upperLimit":"-2.2"}]}]},{"title":"Week 4 (n=102)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","lowerLimit":"-4.8","upperLimit":"-3.0"}]}]},{"title":"Week 8 (n=99)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","lowerLimit":"-4.9","upperLimit":"-3.0"}]}]},{"title":"Week 12 (n=98)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","lowerLimit":"-5.4","upperLimit":"-3.1"}]}]},{"title":"Week 20 (n=95)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","lowerLimit":"-5.6","upperLimit":"-3.4"}]}]},{"title":"Week 28 (n=92)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","lowerLimit":"-5.0","upperLimit":"-2.7"}]}]},{"title":"Week 36 (n=91)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","lowerLimit":"-4.8","upperLimit":"-2.6"}]}]},{"title":"Week 44 (n=87)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","lowerLimit":"-4.4","upperLimit":"-1.9"}]}]},{"title":"Week 52 (n=85)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","lowerLimit":"-4.8","upperLimit":"-2.4"}]}]},{"title":"Week 52 (LOCF, n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","lowerLimit":"-4.8","upperLimit":"-2.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores","description":"The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.\n\nRange: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.","populationDescription":"The full analysis set consists of all participants who received at least one dose of study medication in this long-term study and for whom post-treatment data were available. For study endpoint of efficacy (Week 52), missing values was imputed with the last observation carried forward (LOCF).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Week 2 (n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","lowerLimit":"-1.5","upperLimit":"-0.5"}]}]},{"title":"Week 4 (n=102)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","lowerLimit":"-1.7","upperLimit":"-0.8"}]}]},{"title":"Week 8 (n=99)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","lowerLimit":"-1.8","upperLimit":"-0.9"}]}]},{"title":"Week 12 (n=98)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-2.0","upperLimit":"-1.0"}]}]},{"title":"Week 20 (n=95)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","lowerLimit":"-2.1","upperLimit":"-1.2"}]}]},{"title":"Week 28 (n=92)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","lowerLimit":"-1.8","upperLimit":"-0.9"}]}]},{"title":"Week 36 (n=91)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","lowerLimit":"-1.8","upperLimit":"-0.7"}]}]},{"title":"Week 44 (n=87)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","lowerLimit":"-1.9","upperLimit":"-0.7"}]}]},{"title":"Week 52 (n=85)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","lowerLimit":"-1.9","upperLimit":"-0.9"}]}]},{"title":"Week 52 (LOCF, n=103)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-1.5","upperLimit":"-0.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score","description":"The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from \"does not interfere\" (0) to \"completely interferes\" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale.\n\nChange = observation mean at Week 52 minus baseline mean.","populationDescription":"The full analysis set consists of all participants who received at least one dose of study medication in this long-term study and for whom post-treatment data were available.\n\nThe number of participants who had mBPI at Week 52/ Early Termination was 101 participants (n=101).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, Week 52","groups":[{"id":"OG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","lowerLimit":"-1.9","upperLimit":"-0.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"53 weeks","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","eventGroups":[{"id":"EG000","title":"Pregabalin","description":"Study period consisted of 4-week dose adjustment phase followed by 48-week maintenance and one-week tapering phase. All participants were given pregabalin twice a day (BID) in the morning and evening. Participants first received 75 milligram (mg) of pregabalin in the evening of Day 1, and then 150 mg/day from Day 2 onward during the first week. The dosage could be adjusted to the maintenance dose of 150, 300, 450, or 600 mg/day by one step (±150 mg/day) in consideration of safety and efficacy on pain control during the dose adjustment phase.","seriousNumAffected":19,"seriousNumAtRisk":103,"otherNumAffected":91,"otherNumAtRisk":103}],"seriousEvents":[{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Colonic polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Tooth development disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":103}]},{"term":"Infected skin ulcer","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Mucosal excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":103}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Nasal polyps","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]},{"term":"Ingrowing nail","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":103}]}],"otherEvents":[{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":103}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":103}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":103}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":103}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":103}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":103}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":103}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":103}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":103}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":103}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":103}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":103}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000013119","term":"Spinal Cord Injuries"},{"id":"D000009437","term":"Neuralgia"},{"id":"D000013118","term":"Spinal Cord Diseases"}],"ancestors":[{"id":"D000014947","term":"Wounds and Injuries"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020196","term":"Trauma, Nervous System"},{"id":"D000010523","term":"Peripheral Nervous System Diseases"},{"id":"D000009468","term":"Neuromuscular Diseases"},{"id":"D000010146","term":"Pain"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M17375","name":"Wounds and Injuries","relevance":"LOW"},{"id":"M15606","name":"Spinal Cord Injuries","asFound":"Spinal Cord Injury","relevance":"HIGH"},{"id":"M11750","name":"Multiple Sclerosis","relevance":"LOW"},{"id":"M15105","name":"Sclerosis","relevance":"LOW"},{"id":"M12071","name":"Neuralgia","asFound":"Neuralgia","relevance":"HIGH"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M15605","name":"Spinal Cord Diseases","asFound":"Spinal Cord Diseases","relevance":"HIGH"},{"id":"M12756","name":"Pain","relevance":"LOW"},{"id":"M21713","name":"Trauma, Nervous System","relevance":"LOW"},{"id":"M13122","name":"Peripheral Nervous System Diseases","relevance":"LOW"},{"id":"M12101","name":"Neuromuscular Diseases","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069583","term":"Pregabalin"}],"ancestors":[{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000927","term":"Anticonvulsants"},{"id":"D000002121","term":"Calcium Channel Blockers"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000077264","term":"Calcium-Regulating Hormones and Agents"},{"id":"D000014151","term":"Anti-Anxiety Agents"},{"id":"D000014149","term":"Tranquilizing Agents"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000011619","term":"Psychotropic Drugs"}],"browseLeaves":[{"id":"M476","name":"Pregabalin","asFound":"Help","relevance":"HIGH"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M3936","name":"Anticonvulsants","relevance":"LOW"},{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M5074","name":"Calcium Channel Blockers","relevance":"LOW"},{"id":"M9479","name":"Hormones","relevance":"LOW"},{"id":"M16595","name":"Anti-Anxiety Agents","relevance":"LOW"},{"id":"M14164","name":"Psychotropic Drugs","relevance":"LOW"}],"browseBranches":[{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"AntiConv","name":"Anticonvulsants"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"}]}},"hasResults":true}